ASCO GI 2022 Conference Coverage

 

ASCO GI 2022 Conference Coverage
A

ASCO GI 2022 Phase I/II Study of Regorafenib and Pembrolizumab in Refractory MSS CRC

By ASCO GI 2022 Conference Coverage FEATURING Afsaneh Barzi
By ASCO GI 2022 Conference Coverage FEATURING Afsaneh Barzi
0 views
February 1, 2022
Comments 0
Login to view comments. Click here to Login

Featured Video

10:25
Exelixis

Explore the mechanism of Action of a TKI in HCC

Feat. W. Keiser

Featured Video

20:00
Exelixis

Child-Pugh Classification and its Role in Treatment Decisions in Pat…

Feat. P. Gholam
Videos
12:45
ASCO GI 2022 Conference Coverage

ASCO GI 2022 Biliary Cancer Updates

Feat. K. Spencer
09:37
ASCO GI 2022 Conference Coverage

ASCO GI 2022 Updates in HCC

Feat. S. Sadeghi
05:42
ASCO GI 2022 Conference Coverage

ASCO GI 2022 Pembro +/- Chemo vs. Chemo Alone for PD-L1+ Advanced GC…

Feat. Z. Wainberg
14:06
ASCO GI 2022 Conference Coverage

ASCO GI 2022 on the Emerging Roles of ctDNA as a Tool in Metastatic …

Feat. A. Dasari
08:15
ASCO GI 2022 Conference Coverage

ASCO GI 2022 on a Quality-Adjusted Time Without Symptoms or Toxicity…

Feat. R. Sugarman
11:37
ASCO GI 2022 Conference Coverage

ASCO GI 2022 CRC Cases: Is It Time to De-Intensify Oxaliplatin to Im…

Feat. G. A. Brooks
06:54
ASCO GI 2022 Conference Coverage

ASCO GI 2022 Results From the PREVAIL ctDNA Study: Liquid Biopsy for…

Feat. J. Mencel
13:14
ASCO GI 2022 Conference Coverage

ASCO GI 2022 Highlights on a Multicenter Phase II Study of Neoadjuva…

Feat. R. Kelly
13:50
ASCO Gastrointestinal Cancers Symposium

[PRIVATE - new ASCO version uploaded] ASCO GI 2022 Updates on the En…

Feat. V. Morris
20:21
ASCO GI 2022 Conference Coverage

ASCO GI 2022 Review of the Emerging Roles of ctDNA as a Tool for Ear…

Feat. N. Starling
05:49
ASCO GI 2022 Conference Coverage

ASCO GI 2022 Updates on the Dose-Escalation & Dose-Expansion Stu…

Feat. Y. Y. Janjigian
08:07
ASCO GI 2022 Conference Coverage

ASCO GI 2022 Phase I/II Study of Regorafenib and Pembrolizumab in Re…

Feat. A. Barzi
12:23
ASCO GI 2022 Conference Coverage

ASCO GI 2022 on Chemo and CRT Neoadjuvant Regimens for Locally Advan…

Feat. K. Kato
22:39
ASCO GI 2022 Conference Coverage

ASCO GI 2022 Updates on Integrating New Targeted Therapy Into Locore…

Feat. F. Rocha
05:54
ASCO GI 2022 Conference Coverage

ASCO GI 2022 on mFOLFOX6/Bev +/- Nivo for 1L Treatment of mCRC: Phas…

Feat. H. Lenz
14:00
ASCO GI 2022 Conference Coverage

ASCO GI 2022 on Triplet vs. Doublet Systemic Therapy for Advanced Re…

Feat. H. K. Sanoff
10:58
ASCO GI 2022 Conference Coverage

ASCO GI 2022 Updates on FOLFOX + nab-Paclitaxel (FOLFOX-A) in the Tr…

Feat. A. Benson
05:04
ASCO GI 2022 Conference Coverage

ASCO GI 2022 Updates on IO for Early Stage HCC

Feat. A. Villanueva
05:07
ASCO GI 2022 Conference Coverage

ASCO GI 2022 Long-Term Follow-Up of the GERCOR NIPICOL Study: One-Ye…

Feat. R. Cohen
08:49
ASCO GI 2022 Conference Coverage

ASCO GI 2022 Update on NIVO+ Chemo vs Chemo as 1L Treatment for Adva…

Feat. K. Shitara
07:30
ASCO GI 2022 Conference Coverage

ASCO GI 2022 Updates on IMbrave150 Trial: Exploratory Efficacy &…

Feat. H. Chong Toh
04:05
ASCO GI 2022 Conference Coverage

ASCO GI 2022 Highlights: Host-Related Biomarkers Including Gut Micro…

Feat. Y. Sunakawa
09:44
ASCO GI 2022 Conference Coverage

ASCO GI 2022 Highlights: Clinical Utility of MSI-H Identified on Liq…

Feat. P. Kasi